Ryusei Matsuyama
- Biotechnology top 0.5%
- Cancer Research and Treatments 22
- Oncology top 1%
- Pancreatic and Hepatic Oncology Research 53
- Cancer Immunotherapy and Biomarkers 20
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 15
-
- Gallbladder and Bile Duct Disorders 29
- Ferroptosis and cancer prognosis 13
- Immunology top 5%
-
- Cholangiocarcinoma and Gallbladder Cancer Studies 33
- Pediatric Hepatobiliary Diseases and Treatments 12
- Co-authors
- Itaru EndoMasanori OshiKazuaki TakabeYoshihisa TokumaruLi YanRintaro MoriKuniya TanakaRobert M. Hoffman
- Cited by
- BiotechnologyOncologyCancer Research
- Partner nations
- JapanUnited StatesAustralia
In The Last Decade
Ryusei Matsuyama
156 papers receiving 3.8k citations
Peers
Comparison fields: 5 of 103
- Biotechnology 739
- Oncology 1.8k
- Cancer Research 869
- Pulmonary and Respiratory Medicine 1.2k
- Immunology 592
Countries citing papers authored by Ryusei Matsuyama
This map shows the geographic impact of Ryusei Matsuyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryusei Matsuyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryusei Matsuyama more than expected).
Fields of papers citing papers by Ryusei Matsuyama
This network shows the impact of papers produced by Ryusei Matsuyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryusei Matsuyama. The network helps show where Ryusei Matsuyama may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ryusei Matsuyama, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 9 | |
| 3 | 2022 | 13 | |
| 4 | A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. | 2021 | 10 |
| 5 | 2020 | 41 | |
| 6 | 2020 | 32 | |
| 7 | 2020 | 9 | |
| 8 | 2020 | 4 | |
| 9 | 2019 | 18 | |
| 10 | 2019 | 13 | |
| 11 | 2019 | 10 | |
| 12 | Stroke Volume Variation for the Evaluation of Circulating Blood Volume after Living Donor Liver Transplantation. | 2015 | 1 |
| 13 | 2015 | 27 | |
| 14 | 2012 | 2 | |
| 15 | 2010 | 4 | |
| 16 | 2005 | 1 | |
| 17 | 2004 | 2 | |
| 18 | 2004 | 1 | |
| 19 | 2002 | 3 | |
| 20 | 2002 | 1 |
About Ryusei Matsuyama
Ryusei Matsuyama is a scholar working on Oncology, Biotechnology and Hepatology, having authored 168 papers that have together received 3.8k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (53 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (33 papers), Gallbladder and Bile Duct Disorders (29 papers), Cancer Research and Treatments (22 papers), Cancer Immunotherapy and Biomarkers (20 papers), Cancer Genomics and Diagnostics (15 papers), Ferroptosis and cancer prognosis (13 papers) and Pediatric Hepatobiliary Diseases and Treatments (12 papers). The work is most often cited by research in Biotechnology (739 citations), Oncology (1.8k citations) and Cancer Research (869 citations). Ryusei Matsuyama has collaborated with scholars based in Japan, United States and Australia. Frequent co-authors include Itaru Endo, Masanori Oshi, Kazuaki Takabe, Yoshihisa Tokumaru, Li Yan, Rintaro Mori, Kuniya Tanaka, Robert M. Hoffman, Takashi Murakami and Yasushi Ichikawa.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.